Druggio Logo

Druggio

Astellas Pharma

Astellas Pharma is a global pharmaceutical company with a focus on advancing the field of pharmaceutical research and development. The company is known for its innovative drugs and treatments for various medical conditions, including urology, oncology, immunology, and infectious diseases. Astellas Pharma has a history of developing medications for conditions such as overactive bladder, prostate cancer, transplant rejection, and fungal infections. Founded in 2005 through the merger of two Japanese pharmaceutical companies, Astellas has since expanded its operations to become a well-respected leader in the healthcare industry.

Astellas Pharma's Drugs

Padcev

Approval date

2021/9/27

Evrenzo

Approval date

2019/9/20

Treats

Renal anemia
Smyraf

Approval date

2019/3/26

Evenity

Approval date

2019/1/8

Treats

Osteoporosis
Blincyto

Approval date

2018/9/21

Xospata

Approval date

2018/9/21

Dafclir

Approval date

2018/7/2

Linzess

Approval date

2016/12/19

Repatha

Approval date

2016/1/22

Orfadin

Approval date

2014/12/26

Treats

Tyrosinemia
Xtandi

Approval date

2014/3/24

Suglat

Approval date

2014/1/17

Gonax

Approval date

2012/6/29

Kiklin

Approval date

2012/3/30

Regnite

Approval date

2012/1/18

Betanis

Approval date

2011/7/1

Recalbon, Bonoteo

Approval date

2009/1/21

Treats

Osteoporosis
Celecox

Approval date

2007/1/26

Vesicare

Approval date

2006/4/20

Funguard

Approval date

2002/10/8

Myslee

Approval date

2000/9/22

Treats

Insomnia
Polyful, Colonel

Approval date

2000/7/3